Four Pharmaceutical Companies Release 2025 Q1–Q3 Earnings Forecasts: Three Report Continued Losses, One Turns Profitable

　　【Pharmaceutical Network Industry DynamicsAccording to statistics, as of September 11, four companies in the pharmaceuticals industry have disclosed their earnings forecasts for the first three quarters of 2025. They are Northland, Jinghao, Inner Mongolia Grand Pharmaceutical, and Health Guard. Among them, three companies are expected to report continued net losses for the first three quarters of 2025, while one company is projected to turn from a loss to a profit.
 

　　Northland:The First Three QuartersNet profit will continue to be in loss.

 

Northland announced on August 28 that it expects the net profit attributable to shareholders of the listed company for the first three quarters of 2025 to continue incurring losses.
 

The main reasons for the change in performance are: During the reporting period, the company's main R&D products are still in the drug research and development stage (currently, the application for the marketing authorization of the domestically produced product NL003 under development by the company has been accepted by the National Medical Products Administration). The company’s revenue mainly comes from the sales revenue of eye drops, CMO, and CDMO. However, the parent company is still in the new drug research and development stage, so the overall net profit of the company remains in a loss. It is expected that the company will continue to incur losses from January to September 2025.
 

Public information shows that Northland is an innovative biopharmaceutical enterprise specializing in the research, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
 

　Jinghao Medical: ExpectedThe First Three QuartersNet Profit Turns from Loss to Gain

 

Jinghao Medical announced on August 27 that it expects its net profit for January-September 2025 to turn from a loss to a profit compared to the same period last year.
 

The reason for the change in performance is: the company's net profit for the half-year was 7.2635 million yuan, an increase of 13.4797 million yuan year-on-year, and the net profit for the first three quarters is expected to turn from a loss to a profit compared with the same period last year.
 

Public information shows that Jinghao is a provider of intelligent medical devices, mainly offering healthcare products such as hearing aids, blood pressure monitors, pulse oximeters, nebulizers, and air mattresses.
 

　　Inner Mongolia Grand Pharmaceutical Co.,Ltd.: Expected to Continue Incurring Losses in the First Three Quarters
 

Inner Mongolia Grand Pharmaceutical Co., Ltd. announced on August 27 that due to the continued presence of factors affecting the decline in profits, it is expected that the net profit attributable to shareholders of the listed company for the first three quarters of 2025 will continue to incur losses.
 

The semi-annual report for 2025 shows that during the reporting period, the company achieved operating revenue of 73.8589 million yuan, a year-on-year decrease of 30.04%. The net profit attributable to shareholders of the listed company was a loss of 21.9012 million yuan, turning from profit to loss year-on-year. At that time, the company explained that the main reason for the decline in operating revenue was fierce market competition during the period, leading to a drop in sales prices, which in turn caused a year-on-year decrease in main business revenue. The year-on-year decrease in net profit was mainly due to: firstly, fierce market competition during the period led to a drop in sales prices, which in turn caused a year-on-year decrease in main business revenue; secondly, the increase in fixed cost expenses at the Linhe plant during the period led to an increase in unit costs, which in turn caused a year-on-year increase in main business costs; thirdly, the increase in depreciation expenses allocated by the management department at the Linhe plant during the period led to a year-on-year increase in management expenses.
 

Public information shows that Inner Mongolia Grand Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise mainly engaged in the development of Mongolian medicine resources, research and development, production, and sales of specialty drugs and health products.
 

　　Health Guard: Estimated归属net loss for the first three quarters to continue
 

Health Guard announced on August 21 that it expects the company's net profit attributable to shareholders for January-September 2025 to continue incurring losses.
 

The announcement shows that, as of the end of this reporting period, all vaccine products of the company are still in the research and development stage, with no vaccine products available for market sales yet. The company's main business revenue comes from the sale of testing reagents for scientific research, which has not been sufficient to cover the company’s R&D and daily operational needs. The company has not yet turned a profit and has accumulated uncompensated losses. The commercialization of the company’s R&D projects will still take time, and it is expected that the company will continue to incur losses from January to September 2025.
 

Public information shows that Health Guard is a company mainly engaged in the research, development, and industrialization of structure-based recombinant protein vaccines.
 

Disclaimer: The above content is compiled from publicly available information and generated by AI algorithms. It does not constitute investment advice.